All Posts

Oncology has a “toolbox surplus” but a “systems thinking deficit.” Science increasingly shows cancer behaves like a complex, adaptive biological system (heterogeneous, evolving, shaped by microenvironment + host immunity). But the care and innovation system still behaves as if cancer is a linear, targetable object - and as if diagnosis and local interventions are mostly neutral steps before “real treatment.” Examples of the mismatch • We treat a tumor like a static target, ye

The problem: innovation outpacing evaluation Oncology innovation is moving faster than the systems designed to evaluate it. New therapies are still tested, approved, and delivered through clinical, regulatory, and economic frameworks that have evolved far more slowly than the science itself. When novel approaches struggle to validate under these conditions, this does not necessarily reflect failure of the biology. More often, it reflects a system not yet fully designed to tes

Modern oncology is rich in tools but constrained by models. When cancer behaves as a complex, adaptive system, linear approaches built around isolated interventions predictably fall short. Below are six core insights reshaping oncology , and why the next decade will look very different from the last. 1. Single agents fail because cancer is multi-pathway and adaptive Cancer rarely depends on a single pathway, mutation, or signal. It survives through: redundancy  (backup surviv